Bradford Crutchfield insider trades: 10x Genomics (TXG) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Bradford reports to the SEC
Open-market buys and sales
41 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 23, 2022 | TXG | ↓ Sell | 286 | $48.76 | $14K | Direct | May 25, 2022 (2d) |
| May 13, 2022 | TXG | ↑ Buy | 158 | $40.49 | $6K | Direct | May 17, 2022 (4d) |
| Feb 22, 2022 | TXG | ↓ Sell | 288 | $78.60 | $23K | Direct | Feb 24, 2022 (2d) |
| Feb 15, 2022 | TXG | ↓ Sell | 17,000 | $95.13 | $1.6M | Direct | Feb 17, 2022 (2d) |
| Jan 12, 2022 | TXG | ↓ Sell | 17,000 | $119.00 | $2.0M | Direct | Jan 14, 2022 (2d) |
| Dec 13, 2021 | TXG | ↓ Sell | 17,000 | $139.36 | $2.4M | Direct | Dec 15, 2021 (2d) |
| Nov 22, 2021 | TXG | ↓ Sell | 281 | $148.38 | $42K | Direct | Nov 24, 2021 (2d) |
| Nov 12, 2021 | TXG | ↓ Sell | 17,000 | $164.92 | $2.8M | Direct | Nov 16, 2021 (4d) |
| Oct 12, 2021 | TXG | ↓ Sell | 17,000 | $157.30 | $2.7M | Direct | Oct 14, 2021 (2d) |
| Sep 13, 2021 | TXG | ↓ Sell | 17,000 | $174.49 | $3.0M | Direct | Sep 15, 2021 (2d) |
| Aug 23, 2021 | TXG | ↓ Sell | 270 | $161.85 | $44K | Direct | Aug 25, 2021 (2d) |
| Aug 12, 2021 | TXG | ↓ Sell | 17,000 | $159.69 | $2.7M | Direct | Aug 16, 2021 (4d) |
| Jul 12, 2021 | TXG | ↓ Sell | 17,000 | $186.53 | $3.2M | Direct | Jul 14, 2021 (2d) |
| Jun 14, 2021 | TXG | ↓ Sell | 17,000 | $191.69 | $3.3M | Direct | Jun 16, 2021 (2d) |
| May 24, 2021 | TXG | ↓ Sell | 281 | $162.66 | $46K | Direct | May 26, 2021 (2d) |
| May 12, 2021 | TXG | ↓ Sell | 17,000 | $134.78 | $2.3M | Direct | May 13, 2021 (1d) |
| Apr 12, 2021 | TXG | ↓ Sell | 17,000 | $185.89 | $3.2M | Direct | Apr 13, 2021 (1d) |
| Mar 12, 2021 | TXG | ↓ Sell | 17,000 | $157.01 | $2.7M | Direct | Mar 16, 2021 (4d) |
| Feb 1, 2021 | TXG | ↓ Sell | 17,000 | $175.99 | $3.0M | Direct | Feb 3, 2021 (2d) |
| Jan 4, 2021 | TXG | ↓ Sell | 17,000 | $139.93 | $2.4M | Direct | Jan 6, 2021 (2d) |
| Dec 1, 2020 | TXG | ↓ Sell | 17,000 | $151.29 | $2.6M | Direct | Dec 3, 2020 (2d) |
| Nov 3, 2020 | TXG | ↓ Sell | 17,000 | $136.68 | $2.3M | Direct | Nov 4, 2020 (1d) |
| Oct 1, 2020 | TXG | ↓ Sell | 17,000 | $125.43 | $2.1M | Direct | Oct 5, 2020 (4d) |
| Sep 2, 2020 | TXG | ↓ Sell | 17,000 | $113.67 | $1.9M | Direct | Sep 3, 2020 (1d) |
| Aug 3, 2020 | TXG | ↓ Sell | 17,000 | $99.33 | $1.7M | Direct | Aug 5, 2020 (2d) |
| Jul 1, 2020 | TXG | ↓ Sell | 17,000 | $87.60 | $1.5M | Direct | Jul 2, 2020 (1d) |
| Jun 1, 2020 | TXG | ↓ Sell | 17,000 | $79.84 | $1.4M | Direct | Jun 3, 2020 (2d) |
| May 1, 2020 | TXG | ↓ Sell | 17,000 | $77.38 | $1.3M | Direct | May 5, 2020 (4d) |
| Apr 1, 2020 | TXG | ↓ Sell | 17,000 | $58.06 | $987K | Direct | Apr 3, 2020 (2d) |
| Mar 6, 2020 | TXG | ↓ Sell | 17,000 | $65.91 | $1.1M | Direct | Mar 9, 2020 (3d) |
| Sep 10, 2012 | BIO | ↓ Sell | 92 | $103.49 | $10K | Direct | Sep 11, 2012 (1d) |
| Aug 20, 2012 | BIO | ↓ Sell | 4,000 | $103.11 | $412K | Direct | Aug 21, 2012 (1d) |
| Jun 12, 2012 | BIO | ↓ Sell | 87 | $96.51 | $8K | Direct | Jun 13, 2012 (1d) |
| Jun 11, 2012 | BIO | ↓ Sell | 89 | $96.49 | $9K | Direct | Jun 12, 2012 (1d) |
| Nov 16, 2011 | BIO | ↓ Sell | 4,000 | $97.93 | $392K | Direct | Nov 18, 2011 (2d) |
| Jun 14, 2011 | BIO | ↓ Sell | 87 | $117.53 | $10K | Direct | Jun 15, 2011 (1d) |
| Mar 2, 2011 | BIO | ↓ Sell | 4,000 | $113.01 | $452K | Direct | Mar 3, 2011 (1d) |
| Nov 12, 2009 | BIO | ↓ Sell | 2,000 | $99.09 | $198K | Direct | Nov 13, 2009 (1d) |
| Aug 4, 2009 | BIO | ↓ Sell10b5-1 | 86 | $76.01 | $7K | Direct | Aug 6, 2009 (2d) |
| Jun 4, 2007 | BIO | ↓ Sell | 8,200 | $74.30 | $609K | Direct | Jun 6, 2007 (2d) |
| Nov 10, 2005 | BIO | ↓ Sell | 2,000 | $59.55 | $119K | Direct | Nov 10, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TXG insiders
Open-market trades in the last 12 months
About Bradford Crutchfield's insider trades
Bradford Crutchfield is Chief Commercial Officer at 10x Genomics (TXG). Since Nov 10, 2005, Bradford has reported 1 open-market purchase worth $6K and 40 sales worth $56.4M on SEC Form 4. There have been no open-market trades in the last 12 months.
1 sale (0% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include option exercises (44 filings), grants and awards (12 filings), shares withheld for taxes (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TXG insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.